<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Individuals carrying type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk alleles in TCF7L2 display decreased beta cell levels of T cell factor 7 like-2 (TCF7L2) immunoreactivity, and <z:e sem="disease" ids="C0948379" disease_type="Disease or Syndrome" abbrv="">impaired insulin secretion</z:e> and beta cell sensitivity to glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we sought to determine whether selective deletion of Tcf7l2 in mouse pancreas impairs insulin release and <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Pancreas-specific Tcf7l2-null (pTcf7l2) mice were generated by crossing mice carrying conditional knockout alleles of Tcf7l2 (Tcf7l2-flox) with mice expressing Cre recombinase under the control of the Pdx1 promoter (Pdx1.Cre) </plain></SENT>
<SENT sid="3" pm="."><plain>Gene expression was assessed by real-time quantitative PCR and beta cell mass by optical projection tomography </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> tolerance, insulin secretion from isolated islets, and plasma insulin, glucagon and GLP-1 content were assessed by standard protocols </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: From 12 weeks of age, pTcf7l2 mice displayed decreased oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance vs control littermates; from 20 weeks they had <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> upon administration of <z:chebi fb="105" ids="17234">glucose</z:chebi> by the intraperitoneal route </plain></SENT>
<SENT sid="6" pm="."><plain>pTcf7l2 islets displayed <z:e sem="disease" ids="C0948379" disease_type="Disease or Syndrome" abbrv="">impaired insulin secretion</z:e> in response to 17 (vs 3.0) mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi> (54.6 ± 4.6%, p &lt; 0.01) or to 17 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi> plus 100 nmol/l GLP-1 (44.3 ± 4.9%, p &lt; 0.01) compared with control islets </plain></SENT>
<SENT sid="7" pm="."><plain>Glp1r (42 ± 0.08%, p &lt; 0.01) and Ins2 (15.4 ± 4.6%, p &lt; 0.01) expression was significantly lower in pTcf7l2 islets than in controls </plain></SENT>
<SENT sid="8" pm="."><plain>Maintained on a high-fat (but not on a <z:mpath ids='MPATH_458'>normal</z:mpath>) diet, pTcf7l2 mice displayed decreased expansion of pancreatic beta cell volume vs control littermates </plain></SENT>
<SENT sid="9" pm="."><plain>No differences were observed in plasma insulin, proinsulin, glucagon or GLP-1 concentrations </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: Selective deletion of Tcf7l2 in the pancreas replicates key aspects of the altered <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis in human carriers of TCF7L2 risk alleles, indicating the direct role of this factor in controlling beta cell function </plain></SENT>
</text></document>